NSE · BROOKS
Brooks Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹23 Cr with net profit ₹1 Cr — a 6.18% net margin, versus 28.29% the period before.
Shareholding
As of 2026-09-30
- Promoter52.62%
- Public37.44%
- FII0.04%
- DII9.9%
11,253 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.1× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #66 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Brooks Laboratories Ltd.(this company) | ₹186 Cr | 14.09 | 1.54 | 20.04% | 15.88% |
AI analysis
AI-generated · google/gemini-2.5-flashBrooks Laboratories Ltd. is listed on the Indian markets with a market capitalization of Rs 200 Cr. The company reported revenue of Rs 83.44 Cr and a profit margin of 28.67%. Its earnings per share (EPS) stands at Rs 8.35.
Positives
- +The company's profit margin is 28.67%.
- +The debt-to-equity ratio is low at 0.08.
- +Promoter holding is 52.62% as of Jun 30, 2026.
Negatives
- −The price-to-earnings (PE) ratio is high at 130.29.
- −The company is under ESM Stage 1 surveillance.
- −Revenue growth for the latest reported period is 3.9%, which is relatively modest.
Financial performance
Brooks Laboratories Ltd. reported revenue of Rs 83.44 Cr, representing a growth of 3.9%. Net profit for the period was Rs 23.95 Cr. The quarterly revenue for Mar 2026 was Rs 20.21 Cr, with a net profit of Rs 1.52 Cr. The company's highest quarterly revenue in the provided data was Rs 25.51 Cr in Jun 2025.
Profitability & returns
The company’s profit margin is 28.67%. Return on equity (ROE) is 20.04%, and return on capital employed (ROCE) is 19.30%. The earnings per share (EPS) is Rs 8.35. The price-to-earnings (PE) ratio stands at 130.29.
Balance sheet
Brooks Laboratories Ltd. has a book value per share of Rs 41.64. The debt-to-equity ratio is 0.08, indicating a low level of debt relative to equity. No dividend yield was reported for the company.
Ownership & pledges
Foreign Institutional Investors (FIIs) have a minor stake of 0.0032%. There are no reported promoter share pledges.
Regulatory & surveillance
Brooks Laboratories Ltd. is currently under ESM Stage 1 surveillance, which includes measures like additional surveillance for market integrity and investor protection. The security is subject to ESM measures.
Data as of — price: 2026-11-07 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.